Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.

Martin WasserbauerŠtěpán HlavaMilan TrojanekJan StovicekTomáš MilotaJiri DrabekPetra KoptováAndrea CupkovaDita PichlerováBarbora KucerovaStepan CoufalRadan Keil

Published in: PloS one (2022)

Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy. Statistically significant differences between our groups of patients were not proved.

Keyphrases

patients with inflammatory bowel disease
sars cov
end stage renal disease
newly diagnosed
respiratory syndrome coronavirus
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
bone marrow
mesenchymal stem cells